ARGX vs ALNY

For growth investors, argenx SE (ARGX) is the stronger pick with 90.

1% revenue growth year-over-year, versus 65. 2% for Alnylam Pharmaceuticals, Inc. (ALNY). argenx SE (ARGX) offers the better valuation at 40. 1x trailing P/E (30. 0x forward), making it the more compelling value choice. Analysts rate argenx SE (ARGX) a "Buy" — based on 36 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, argenx SE (ARGX) is the cheapest at 40.

1x versus Alnylam Pharmaceuticals, Inc. at 127. 0x. On forward P/E, argenx SE is actually cheaper at 30. 0x.

Over the past 5 years, argenx SE (ARGX) delivered a total return of +198.

6%, compared to +125. 4% for Alnylam Pharmaceuticals, Inc. (ALNY). Over 10 years, the gap is even starker: ARGX returned +33. 2% versus ALNY's +411. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), argenx SE (ARGX) is the lower-risk stock at 0.

52β versus Alnylam Pharmaceuticals, Inc. 's 0. 71β — meaning ALNY is approximately 34% more volatile than ARGX relative to the S&P 500. On balance sheet safety, argenx SE (ARGX) carries a lower debt/equity ratio of 1% versus 162% for Alnylam Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), argenx SE (ARGX) is pulling ahead at 90.

1% versus 65. 2% for Alnylam Pharmaceuticals, Inc. (ALNY). On earnings-per-share growth, the picture is similar: Alnylam Pharmaceuticals, Inc. grew EPS 206. 9% year-over-year, compared to 53. 6% for argenx SE. Over a 3-year CAGR, ARGX leads at 116. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

argenx SE (ARGX) is the more profitable company, earning 31.

1% net margin versus 8. 4% for Alnylam Pharmaceuticals, Inc. — meaning it keeps 31. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ARGX leads at 23. 4% versus 13. 5% for ALNY. At the gross margin level — before operating expenses — ARGX leads at 89. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, argenx SE (ARGX) trades at 30.

0x forward P/E versus 44. 2x for Alnylam Pharmaceuticals, Inc. — 14. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ALNY: 50. 6% to $445. 67.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Alnylam Pharmaceuticals, Inc.

(ALNY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 71), +411. 9% 10Y return). Both have compounded well over 10 years (ALNY: +411. 9%, ARGX: +33. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.